Memgen, Inc.
HOUSTON, TX · CIK 0001760644 · Software
Decentralised AI platform for art generation and autonomous AI agents on blockchain
memgen.io →- Grants
- —
- No SBIR or STTR on record
- Sector median: 0
- Raised
- $12M
- 6 Form D · Dec 2024
- 22 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 5
- 1 granted · 4 pending
- Sector median: 0
Capital Timeline
Federal ↑Equity ↓20182019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $715,003 | |
| Private capital raised | Form D · SEC | $350,000 | |
| Private capital raised | Form D · SEC | $50,000 | |
| Private capital raised | Form D · SEC | $9,767,223 | |
| Private capital raised | Form D · SEC | $624,979 | |
| Private capital raised | Form D · SEC | $950,002 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1728 | PEAK BEVERAGE HOLDINGS, INC. | — | $50K |
| 1729 | Mattereum Group Ltd | — | $275K |
| 1730 | TerraScale Inc. | — | $8.8M |
| 1731 | Memgen, Inc. | — | $12M |
| 1732 | Grayscale Labs, Inc. | — | $8.3M |
| 1733 | Hybrico Energy Technologies, Inc. | — | $3.2M |
| 1734 | Aiera, Inc. | — | $32M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Patricia BitarDirector
- Gregory BrownDirector · Executive Officer
- Mark CantwellDirector · Executive Officer
- Robert CoatesDirector · Executive Officer
- Kevin CoveneyExecutive Officer
- Casey LoganDirector
- Christopher PaganoDirector
- John PoulosDirector
- Steven WhitleyDirector
Patents
- Oncolytic Virus Or Antigen Presenting Cell Mediated Cancer Therapy Using Type I Interferon And CD40-LIGANDgranted
- Enhancing Immunity Using Chimeric CD40 Ligand and Coronavirus Vaccineapplication
- Oncolytic Virus Boosts T Cell Response For Effective Til Therapyapplication
- Enhancing Immunity Using Chimeric CD40 Ligand And Coronavirus Vaccineapplication
- Enhancing Immunity Using Chimeric CD40 Ligand and Coronavirus Vaccineapplication